polpotal	· <b>y</b> •
It is made available under a CC-B	Y 4.0 International license.

1		Strong early impact of letrozole on ovulation induction
2		outperforms clomiphene citrate in polycystic ovary
3		syndrome: a systematic review with meta-analysis
4		
5		
6	Rit	a Zsuzsanna Vajna <sup>1,2</sup> , András Mihály Géczi <sup>1,2</sup> , Fanni Adél Meznerics <sup>2,4</sup> , Nándor Ács <sup>1,2</sup> ,
7	Pé	ter Hegyi <sup>2,5,6</sup> , Emma Zoé Feig <sup>2</sup> , Péter Fehérvári <sup>2,7</sup> , Szilvia Kiss-Dala <sup>2</sup> , Szabolcs Várbíró <sup>1,2</sup> ,
8	Juo	lit Réka Hetthessy <sup>3</sup> ¶, Levente Sára <sup>1,2*¶</sup>
9		
10		
10		
11		
12	1.	Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
13		
14	2.	Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
16 17	3.	Department of Orthopaedics, Semmelweis University, Budapest, Hungary
18 19	4.	Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
20 21	5	Institute of Pancreatic Diseases, Semmelweis University, Budanest, Hungary
22		institute of Landreaute Diseases, Seminerweis Chryeisity, Dudupest, Hungary
23 24	6.	Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary
25 26	7.	Department of Biomathematics and Informatics, University of Veterinary Medicine, Budapest, Hungary
27	NC	TE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

	P1	sipotany.		
It is made	available under a	a CC-BY 4	.0 International	license .

28	*Corresponding author
29	E-mail: saralevente@icloud.com (LS)
30	
31	
32	<sup>¶</sup> Equal contribution, therefore, the authors should be considered as co-last authors
33	
34	
35	Acknowledgments
36	None.
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	

#### 54 Conflict of interest

55 None to declare.

#### 56 **CRediT author contribution statement**

- 57 RZSV: conceptualisation, project administration, methodology, formal analysis, writing –
- original draft; AMG: conceptualisation, data curation, writing review & editing; FAM:
- 59 conceptualisation; supervision; writing original draft; NÁ: conceptualisation, writing –
- 60 review & editing; PH: conceptualisation, writing review & editing; EZF: conceptualisation,
- 61 data curation, writing review & editing; **PF:** conceptualization and design of the study, data
- 62 curation, writing review & editing; SZK-D: conceptualisation, data curation, writing -
- 63 review & editing; SZV: conceptualisation, formal analysis, visualization, writing review &
- editing; **JRH**: conceptualisation, writing -review & editing; **LS**: conceptualisation;
- 65 supervision; writing original draft
- 66 Funding
- 67 This research did not receive any specific grant from funding agencies in the public,
- 68 commercial, or not-for-profit sectors.

#### 69 Disclosure Statement

70 None.

#### 71 Ethical approval

72 No ethical approval was required for this systematic review with meta-analysis, as all data

- 73 were already published in peer-reviewed journals. No patients were involved in the design,
- 74 conduct, or interpretation of our study.
- The datasets used in this study can be found in the full-text articles included in the systematicreview and meta-analysis.

#### 77 Abstract

**Background:** Polycystic ovary syndrome is one of the most frequent endocrinological problems causing infertility in women worldwide. The main problem in these women is hyperandrogenism and/or chronic oligo/anovulation, which leads to infertility. In this systematic review and meta-analysis, we aimed to investigate the efficacy of a relatively new drug for ovulation induction, letrozole, by comparing it to the first line of treatment for ovulation induction, clomiphene citrate.

Methods: A literary search was conducted in three databases and included randomized clinical trials comparing letrozole and clomiphene citrate for ovulation induction for women with polycystic ovary syndrome. The diagnosis of polycystic ovary syndrome was determined according to the Rotterdam criteria. We pooled data using a random-effects model.

**Results:** Our search provided a total of 1,994 articles, of which we included 25 studies. In the 88 89 letrozole group, endometrial thickness was significantly higher (Mean Difference=1.70, Confidence Interval: 0.55-2.86; Heterogeinity: I<sup>2</sup>=97%, p-value=0.008); odds for ovulation 90 (Odds Ratio=1.8, Confidence Interval: 1.21-2.69; Heterogeinity: I<sup>2</sup>=51%, p-value=0.010) and 91 pregnancy (Odds Ratio=1.96, Confidence Interval: 1.37-2.81; Heterogeinity: I<sup>2</sup>=32%, p-92 value=0.002) were significantly higher; the resistance index of subendometrial arteries was 93 significantly lower (Mean Difference=-0.15, Confidence Interval: -0.27- -0.04; Heterogeneity: 94 I<sup>2</sup>=92%, p-value=0.030). 95

96 **Conclusion:** Women with polycystic ovary syndrome treated with letrozole for ovulation 97 induction had higher ovulation and pregnancy rates, their endometrium became thicker, the 98 resistance index of subendometrial arteries was lower. The lower resistance index of the 99 subendometrial arteries can improve intrauterine circulation, which may provide better 100 circumstances for embryo implantation and development.

#### Keywords: Chlomiphene citrate; Letrozole; Ovulation induction; Polycystic ovary

#### syndrome; Subendometrial blood flow

# 107 Introduction

108 Polycystic ovary syndrome (PCOS) is one of the most frequent endocrinological problems

- 109 causing infertility in women worldwide [1-4]; the prevalence of this disease is between 9 and
- 110 18% [5]. The main features of the disease are hyperandrogenism and/or chronic
- 111 oligo/anovulation, which leads to infertility [6, 7].
- 112 Clomiphene citrate (CC) has been used since 1960 as a first-line medication for ovulation
- induction (OI) for women with PCOS [8, 9]. However, it has some unpleasant and non-dose-
- dependent side effects, such as hot flashes, increase in ovarian size, bloating, nausea and
- vomiting, breast sensitivity and pain, headaches, hair loss, insomnia, and depression [10].

116 Because of the longer half-life of CC, pregnancy may not occur despite ovulation, perhaps

- due to its antiestrogenic effects on the endocervix and the endometrium [5, 8, 11].
- 118 Letrozole (LE) is a third-generation aromatase inhibitor, an approved adjuvant when treating
- estrogen receptor-positive breast cancer. [12-15]. LE does not show anti-estrogenic effects
- 120 [16, 17] and has minor side effects such as leg cramps and headaches [18, 19]. LE is cleared
- from the circulation faster, with a shorter half-life compared to CC [8]. The aromatase
- inhibition develops, endometrium receptors are up-regulated and rapid endometrial growth is
- 123 observed without adverse effects on endometrium receptivity [8, 15]. Better blood supply to
- the sub-endometrial halo and to the endometrium results in a thicker endometrial wall, thus
- maximizing the odds of pregnancy [20].

Despite its many beneficial properties, LE is not yet included in the first-line therapy of PCOS
patients and little information is available on its effectiveness. Therefore, we aimed to
investigate the efficacy of LE on ovulation rate, endometrial receptivity, and pregnancy rate
in women with PCOS compared to the effects of CC by performing a systematic review and
meta-analysis.

### 131 Methods

- 132 We describe our systematic review and meta-analysis based on the recommendations of the
- 133 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020
- 134 guidelines (S2 Table) [21], while we followed the Cochrane Handbook's recommendations
- 135 for Systematic Reviews of Interventions Version 6.1.0 [22]. The protocol of the study was
- registered on PROSPERO (registration number CRD42022376611; see
- 137 https://www.crd.york.ac.uk/PROSPERO); the protocol was strictly adhered to, additionally,
- 138 we conducted a post-hoc analysis including 12 additional outcomes indicated in the
- 139 population-intervention-control-outcome (PICO) to provide a comprehensive overview of all
- 140 potentially important outcomes.

#### 141 Literature search and eligibility criteria

- 142 We completed our systematic literature search in three medical databases: MEDLINE (via
- 143 PubMed), Cochrane Library (CENTRAL), Embase, from inception to 21 November 2022.
- 144 We applied the query '(polycystic ovarian syndrome OR PCOS OR Stein-Leventhal
- syndrome) AND (letrozole OR aromatase inhibitor)' to all fields in the search engines.
- 146 Neither language nor other restrictions were imposed.
- 147 Randomized clinical trials (RCTs) comparing LE to CC were included for patients diagnosed
- 148 with PCOS based on Rotterdam criteria (at least two years after menarche) [23], comparing
- 149 LE to CC were included. The following PICO agenda was applied:
- 150 P: women with PCOS
- 151 I: LE
- 152 C: CC

O: outcomes according to the protocol: endometrial thickness (ET); number of dominant 153 154 follicles; ovulation rate; pregnancy rate; endometrial volume; additional outcomes: endometrial pattern- and echogenicity; diameter of dominant follicles; rate of mono-and 155 multifollicular development; single and multiple pregnancy rate; live birth rate; miscarriage 156 rate; prevalence of ectopic pregnancies; number of fetal anomalies; endometrial 157 vascularization index, flow index, vascularization flow index and detection rate of 158 endometrial-subendometrial blood flow; resistance index (RI) and pulsatility index (PI) of 159 subendometrial and uterine arteries; systolic velocity/diastolic velocity of subendometrial 160 arteries; biomarker /vascular endothelial growth factor and integrin alpha vß3/ concentrations 161 in uterine fluid 162

Reviews, cases series, cases reports; studies including patients without PCOS diagnosis, girls
before menarche, and those within two years past menarche were excluded from the study.

#### 165 Study selection and data collection

The selection was performed by two independent reviews (RZSV and EZF). Data from the 166 eligible articles were collected by two authors (RZSV and AMG) independently. The 167 following data were extracted about the study: first author; study type; the year of 168 publications; study population; study period. The following data were extracted about patients 169 studied: age; body mass index; duration of infertility; if ovulation was supported with human 170 chorionic gonadotropin or the luteal phase with progesterone; the time interval for 171 endometrial testing in relation to the cycle; the dose of LE or CC and the time of their 172 administration in relation to the cycle, and data on the outcomes. 173

#### 174 Study risk of bias assessment

175 Two authors (RZSV and AMG) performed the risk of bias assessment independently. Risk of

bias was measured using the Risk of Bias Tool 2 [23], as recommended by the Cochrane

177 Collaboration . The quality assessment of the studies included was accomplished according

to the "Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)"

179 workgroup with GRADE-Pro, as recommended by the Cochrane Collaboration [24].

#### 180 Synthesis methods

181 Statistical analysis was conducted using the R 4.1.2. [25] and meta [26] and dmetar packages

182 [27].

183 Letrozole and clomiphene citrate were compared by calculating the mean differences of

184 endometrial thickness, number of dominant follicles, diameter of dominant follicles, RI of

subendometrial artery and PI of subendometrial artery between the intervention and the

186 control groups. Ovulation rate, pregnancy rate, single pregnancy rate, frequency of

187 miscarriages, frequency of monofollicular and mutlifollicular development were also

188 examined. The following outcomes were also analyzed separately in patients who ovulated

189 only: ET, number of dominant follicles, and pregnancy rate.

190 For binary outcomes, odds ratios with 95% confidence intervals (CI) were used as outcome

191 measures. The number of patients and events was extracted or calculated. The results are

192 presented as the odds of an event in the letrozole group compared to the odds of the same

193 event in the clomiphene citrate group.

194 For continuous data, differences in mean values were used with 95% confidence intervals.

195 To calculate mean differences, sample sizes, mean and standard deviation values were

196 extracted from the studies. Mean differences were calculated by extracting the mean values of

197 the clomiphene citrate group from the mean values of the letrozole group.

Pooled OR was calculated with the Mantel-Haenszel method [28] and Robins, Greenland, and Breslow [29]. The exact Mantel-Haenszel method [28] (without continuity correction) was used to handle zero cell counts as recommended by Cooper, Hedges, and Valentine [30] and J. Sweeting, J. Sutton, and C. Lambert [31]. Confidence intervals were created with the Paule-Mandel method [32], recommended by Veroniki et al. [33]. In case of 0 cell counts, individual study odds ratios with 95% confidence intervals were calculated by adding 0.5 as continuity correction (it was used only for visualization on forest plots).

205 Pooled mean differences were computed with the inverse variance method.

The restricted maximum-likelihood estimator was used with the Q profile method for confidence intervals by Harrer et al. [34] and Veroniki et al. [33]. Hartung-Knapp adjustments were also applied [35] and IntHout, Ioannidis, and Borm [36].

Between-study heterogeneity was assessed with the Higgins and Thompson's I<sup>2</sup> [37] statistic and the Cochrane Q test recommended by Harrer et al. [34]. The I 2 statistic shows what percentage of heterogeneity cannot be explained by random chance. Heterogeneity is considered substantial if I 2 exceeds 75%.

#### 213 **Publication bias and heterogeneity**

Publication bias was measured using funnel plots and Egger's test [38, 39]. In case of
endometrial thickness and pregnancy rate. The funnel plots do not indicate publication bias
and the result of Egger's test was not significant, which means publication bias could not be
detected.

218 In case of endometrial thickness, number of dominant follicles and diameter of dominant

follicles, RI of subendometrial artery and PI of subendometrial artery substantial

heterogeneity could be observed. Other outcome measures showed low or moderate

221 heterogeneity.

# 222 **Results**

#### 223 Search and selection

- We found 1,994 articles as a result of our systematic search. After duplicate removal, title
- and abstract selection was performed on 1274 articles. Finally, we included 22 [1, 4, 15, 16,
- 226 19, 40-55] studies after full-text selection, and three additional studies based on citation
- search [5, 6, 56]. The details of the search and selection process are visualized in Fig 1.

### 228 Characteristics of the included studies

229 Baseline and patient characteristics of the studies included in the systematic review and meta-

analysis are detailed in **Table 1**.

231

- 232
- 233

Author (year)	Study site	N° of PP analyzed patients	N° of PP analyzed patients in LE group	N° of PP analyzed patients in CC group	Follow-up period (Number of treatment cycles)	Age (years) in LE group	Age (years) in CC group	BMI (kg/m2) in LE group	BMI (kg/m2) in CC group	Duration of infertility (years) in LE group	Duration of infertility (years) in CC group	Dosage of LE (mg/die)	Dosage of CC (mg/die)	Administration period of LE (day of cycle)	Administration period of LE (day of cycle)	Trigger of ovulation with HCG	Support of luteal phase with progesterone
Studies includ	ed in the meta-	-analysis															
Al-Obaidi et al. [15]	Iraq	80	40	40	1	28.45±5.95 ‡ (PP)	29.58±5.81 ‡ (PP)	25.29±2.76 ‡ (PP)	24.87±2.85 ‡ (PP)	3.53±1.87 ‡ (PP)	3.5±1.88 ‡ (PP)	5	100	3-7.	3-7.	Y	NA
Atay et al. [40]	Turkey	106	51	55	1	27.1±0.9 ‡ (PP)	26.2±1.1 ‡ (PP)	26.1±1.91 ‡ (PP)	25.8±1.77 ‡ (PP)	2.2±0.7 ‡ (PP)	2.4±0.9 ‡ (PP)	2.5	100	3-7.	3-7.	Y	NA
Dehbashi et al. [56]	Iran	100	50	50	1	23.62±2.92 ‡ (PP)	24.32±3.43 ‡ (PP)	27.45±4.61 ‡ (PP)	27.09±3.61 ‡ (PP)	2±1.34 ‡ (PP)	2.3±1.85 ‡ (PP)	5	100	3-7.	3-7.	Y	NA
Elsedeek et al. [4]	Egypt	116	59	57	1	24.95±3.11‡ (PP)	25±3.59 ‡ (PP)	27.7±3.48 ‡ (PP)	29.18±3.47 ‡ (PP)	NA	NA	5	100	3-7.	3-7.	N	NA
Ghahiri et al. [6]	Iran	101	50	51	1	25.63 ± 4.41 (LE + CC group) ‡ (PP)	25.63 ± 4.41 (LE + CC group) ‡ (PP)	28.24±5.2 ‡ (PP)	27.13±4.9 ‡ (PP)	1: 6* (12**); >1: 44* (88**) (PP)	1: 4* (8**); >1: 47* (92**) (PP)	5	100	3-7.	3-7.	NA	NA
Hendawy et al. [41]	Egypt	54	28	26	1	27.2 ± 5.18 ‡ (ITT)	25.21 ± 5.18 ‡ (ITT)	26.2 ± 1.8 ‡ (ITT)	29.1 ± 2.3 ‡ (ITT)	NA	NA	2.5	100	3-7.	3-7.	Y	Y
Hussein et al. [42] ^	Iraq	80	40	40	1	28.45±5.95 ‡ (PP)	29.58±5.81 ‡ (PP)	25.29±2.76 ‡ (PP)	24.87±2.85 ‡ (PP)	3.53±1.87 ‡ (PP)	3.5±1.88 ‡ (PP)	5	100	3-7.	3-7.	Y	NA
Kar [43]	India	103	52	51	1	26.26±2.41 ‡ (PP)	26.27±2.47 ‡ (PP)	25.91±3.57 ‡ (PP)	25.95±3.31 ‡ (PP)	3.08±1.92 ‡ (PP)	3.14±2.16 ‡ (PP)	5	100	2-6.	2-6.	Y	Y
Khakhwani et al. [44]	Pakistan	70	36	34	1	≤20: 5* (12.8**); 21- 30: 34* (87.2**) (ITT)	≤20: 3* (7.7**); 21- 30: 36* (92.3**) (ITT)	<25: 24* (61.5**); >25: 15* (38.5**) (ITT)	<25: 28* (71.8**); >25: 11* (28.2**) (ITT)	<pre>&lt;3: 30** (76.9**); ≥3: 9* (23.1**) (ITT)</pre>	<3: 30* (76.9**); ≥3: 12* (30.8**) (ITT)	5	100	3-7.	3-7.	NA	NA
Morbusher [45]	Pakistan	100	50	50	1	24.29±2.3 ‡ (PP)	24.26±2.33 ‡ (PP)	25.91±3.32 ‡ (PP)	25.89±3.31 ‡ (PP)	3.18±2.12 ‡ (PP)	3.12±2.02 ‡ (PP)	2.5	100	2-6.	2-6.	Y	Y

# Table 1. Basic characteristics of the studies included in the systematic review and meta-analysis

Najafi et al. [16]	Iran	220	110	110	1		26.2±3.6 ‡ (PP)	27±3.6 ‡ (PP)	27.6±1.8 ‡ (PP)	27.3±1.8 ‡ (PP)	2.1±1.2 ‡ (PP)	2.4±1.3 ‡ (PP)	10	100	3-7.	3-7.	Y	NA
Selim et al. [19]	Saudi Arabia	201	102	99	1		26±2.7 ‡ (PP)	25.1±3.1 ‡ (PP)	24.4±4.3 ‡ (PP)	23.8±3.7 ‡ (PP)	2.9±0.6 ‡ (PP)	2.6±0.7 ‡ (PP)	5	100	3-7.	3-7.	Y	NA
Wang et al. [1]	China	160	80	80	1		29.2±5.1 ‡ (PP)	28.4±4.6 ‡ (PP)	21.4±3.9 ‡ (PP)	22±3.8 ‡ (PP)	2.4±0.89 ‡ (PP)	2.1±0.8 ‡ (PP)	2.5	50	3-7.	3-7.	Y	NA
Wang et al. [5]	China	112	57	55	1		28.5±7.6 ‡ (ITT)	28.3±7.5 ‡ (ITT)	24.9±8.4 ‡ (ITT)	25.3±7.9 ‡ (ITT)	2.4±0.7 ‡ (ITT)	2.3±0.6‡ (ITT)	2.5	50	5-9.	5-9.	Y	NA
Zafar et al. [46]	Pakistan	360	180	180	1		26.61±4.81 ‡ (PP)	27.89±4.24 ‡ (PP)	NA	NA	4.11±3.5‡ (PP)	4.7±3.4 ‡ (PP)	2.5	50	2-6.	2-6.	NA	NA
Studies include	d only in the s	ystematic revie	2W															
Al-Shaikh et al. [47]	Iraq	85	40	45	LE group: 47	CC group: 80	18-40 §§ (LE + CC group) (PP)	18-40 §§ (LE + CC group) (PP)	NA	NA	NA	NA	5	100	25.	25.	NA	NA
Amer et al. [48]	The United Kingdom	149	75	74	LE group: 1 or 6	CC group: 1 or 6	28.3± 4.4 ‡ (ITT)	28.1±4.2‡ (ITT)	27.5 (23.4 -32.2) § (ITT)	27.7 (23.0-31.0) § (ITT)	1.5 (1.0-2.0) § (ITT)	1.5 (1.0-2.0) § (ITT)	2,5->5	50->100	2/4-6/8	2/4-6/8	NA	NA
Bansal et al. [55]	India	80	41	39	LE group: 1 or 3	CC group: 1 or 3	27.0 ± 3.56 ‡ (ITT)	26.0 ± 3.97 ‡ (ITT)	23.90 ± 3.57 ‡ (ITT)	23.10 ± 3.64 ‡ (ITT)	3.9 ± 2.3 <b>‡</b> (ITT)	3.4 ± 2.3 <b>‡</b> (ITT)	2.5->7.5	50->150	2-6.	2-6.	Y	NA
Baruah et al. [57]	India	50	25	25	LE group:	CC group: 56	29.7±0.5 ‡ (PP)	30.2±0.5 ‡ (PP)	23.6±0.04 * (PP)	24.52±0.02 ‡ (PP)	2.7±0.2 ‡ (PP)	2.9±0.5 ‡ (PP)	2.5->5	50->100	5-9.	5-9.	Y	NA

					58													
					LE													
Bayar et al. [49]	Turkey				group:	CC group:												
		74	20	26	00	0.5	32.2 ±3.9 ‡	30.6± 4 ‡	<b>N</b> 74	N14	5 (1-10) §	2 (1 11) 8 (DD)	2.5	100	2.7	2.7	v	
		/4	38	36	99	95	(PP)	(PP)	NA	NA	(PP)	3 (1-11) § (PP)	2.5	100	3-7.	3-7.	Ŷ	NA
					LE													
Legro et al. [50]	The United States				group:	CC group:												
							28.9±4.5 ‡	28.8±4.0 ‡			40.9±38.0 ‡							
		750	374	376	5	5	(PP)	(PP)	35.2±9.5 ‡ (PP)	35.1±9.0 ‡ (PP)	(PP)	42.5±37.6 ‡ (PP)	2.5->7.5	50->150	3-7.	3-7.	NA	NA
					LE													
Ray et al. [54]	India				group:	CC group:												
							28 (19-35) §	29 (20-35) §	28.8 (23.2-34.6)	28.5 (24.2-33.6) §								
		147	69	78	132	156	(PP)	(PP)	§ (PP)	(PP)	2.2 ‡‡ (PP)	2.4 ‡‡ (PP)	2.5	100	3-7.	3-7.	Y	NA
					LE													
Roy et al [51]	India				group:	CC group:			25.8	25 4+1 56		5.8						
							26.1±1.8 ‡	26.5±1.3 ‡	23.0	25.4±1.50	6.4±3.8 ‡	5.0	_					
		204	98	106	294	318	(PP)	(PP)	±2.1 ‡ (PP)	‡ (PP)	(PP)	±3.1 ‡ (PP)	2.5->5	50->100	3-7.	37.	Y	NA
					LE													
Sakar et al. [52]	Turkey				group:	CC group:												
							25.9±4 ‡	24.6±4.4‡			2 (1-12) §							
		323	175	148	1 or 6	1 or 6	(PP)	(PP)	25.4±3.2 ‡ (PP)	24.8±2.9 ‡ (PP)	(PP)	2 (1-11) § (PP)	5	100	2-5.	2-5.	NA	NA
					LE													
Sharief et al. [53]	Iraq				group:	CC group:												
							26.1±1.3 ‡	25.3±2.1 ‡			2.4±0.6 ‡							
		75	35	40	6	6	(PP)	(PP)	28.1±1.91 ‡ (PP)	27.8±1.7 ‡ (PP)	(PP)	2.3±0.4 ‡ (PP)	2,5-5	100-200	3-7.	3-7.	Y	NA

‡ parameters represented as mean with standard deviation

‡‡ parameters represented as mean

§ parameters represented as median (min-max)

§§ parameters represented as min-max

- \* number of patients
- \*\* % of patients
- ITT: data were analyzed intention-to-treat
- PP: data were analyzed per-protocol
- N°: number
- LE: letrozole
- CC: clomiphene citrate
- BMI: body mass index
- Y: yes; NA: no data available; N: no

^: the studied patient population is the same as Al-Obaidi et al. 2019 [15], with patients included in the article; therefore, we only included these results once in our meta-analysis

#### 250 **Results of the quantitative analysis**

- 251 On the basis of the results of 11 studies including 1,651 patients, ET was significantly higher
- 252 in LE group /Mean difference (MD)=1.70, CI: 0.55-2.86; I<sup>2</sup>=97%, p=0.008/ compared to CC
- 253 group (Fig 2A). The subset analysis conducted on only ovulating patients showed thicker
- endometrium in LE group; however, this difference did not reach the level of statistical
- 255 significance /MD=2.2, CI: -0.38-4.78; I<sup>2</sup>=97%, p=0.077/ (S1 Fig).
- Fig 2A) Forest plot for endometrial thickness (ET) all patients. Legend: LE-letrozole;
  CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation;
  CI-confidence interval; p-p-value.
- **S1 Fig. Forest plot for endometrial thickness (ET) ovulating patients only.** Legend: LE-
- letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard
  deviation; CI-confidence interval; p-p-value.
- 262 On the basis of the results of 9 studies including 1,510 patients, odds of ovulation and based
- on the results of 11 studies including 1410 patients, odds of pregnancy were significantly
- higher in LE patients /ovulation rate: odds ratio (OR)=1.80, CI: 1.21-2.69;  $I^2=51\%$ , p=0.010
- 265 (Fig 2B); pregnancy rate: OR=1.96, CI: 1.37-2.81; I<sup>2</sup>=32%, p=0.002 (Fig 2C)/ compared to
- 266 CC patients. In patients who ovulated as a result of the drug therapy used, odds of pregnancy
- 267 were also higher in LE group, but this difference did not reach the level of statistical

268 significance /OR=1.65, CI: 0.40-6.76; I<sup>2</sup>=56%, p=0.337/ (Fig S5).

- 269 Fig 2B) Forest plot for ovulation rate. Legend: LE-letrozole; CC-clomiphene citrate; N-
- 270 number of patients; OR-odds ratio; CI-confidence interval; p-p-value.
- Fig 2C) Forest plot for pregnancy rate all patients. Legend: LE-letrozole; CC-
- clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value.

S5 Fig. Forest plot for pregnancy rate - ovulating patients only. Legend: LE-letrozole; 273 274 CC-clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-pvalue. 275 On the basis of the results of 3 studies including 460 patients, **RI of subendometrial arteries** 276 was significantly lower in LE patients /MD=-0.15, CI: -0.27- -0.04; I<sup>2</sup>=92%, p=0.030/ 277 compared to CC patients (Fig 3A). PI of subendometrial arteries was also lower in the LE 278 group /MD=-0.17, CI: -0.81-0.47;  $I^2$ =95%, p=0.372/, but this difference did not reach the 279 280 level of statistical significance (Fig 3B). Fig 3A) Forest plot for subendomendometrial circulation - resistance index (RI) of 281 subendometrial arteries. Legend: LE-letrozole; CC-clomiphene citrate; N-number of 282 patients; MD-mean difference; SD-standard deviation; CI-confidence interval; p-p-value. 283 Fig 3B) Forest plot for subendomendometrial circulation - pulsatility index (PI) of 284 285 subendometrial arteries. Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; CI-confidence interval; p-p-value. 286 On the basis of the results of 8 studies including 253 patients, odds of multiple pregnancies 287 were higher in CC patients /multiple pregnancies: OR=0.41, CI: 0.12-1.35; I<sup>2</sup>=0%, p=0.119/ 288 289 compared to LE patients (S6 Fig), but this difference did not reach the level of statistical significance. 290 S6 Fig. Forest plot for multiple pregnancy rate. Legend: LE-letrozole; CC-clomiphene 291 citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value. 292 293 On the basis of the results of 4 studies including 160 patients, there was no difference in the 294 miscarriage rate /OR=0.62, CI: 0.19-1.98; I<sup>2</sup>=0%, p=0.278/ (S7 Fig).

S7 Fig. Forest plot for miscarriage rate. Legend: LE-letrozole; CC-clomiphene citrate; Nnumber of patients; OR-odds ratio; CI-confidence interval; p-p-value.

297	There was no significant difference between groups in the <b>number</b> of <b>follicles</b> /MD=-0.40,
298	CI: -0.84-0.03; $I^2=91\%$ , p=0.066/ based on the results of 9 studies including 1264 patients (S2
299	Fig) and the diameter of follicles /MD=0.58, CI: -0.17-1.32; $I^2$ =45%, p=0.092/ based on the
300	results of 4 studies including 660 patients (S4 Fig) although more but smaller follicles were
301	seen in CC group. In the subset analysis of the number of follicles conducted in patients who
302	only ovulated, there was also no significant difference between the two groups /MD=-0.80 CI:
303	-2.48-0.89; I <sup>2</sup> = 80%; p=0.179/ ( <b>S3 Fig</b> ).
304	S2 Fig. Forest plot for number of dominant follicles – all patients. Legend: LE-letrozole;
305	CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation.
306	CI-confidence interval; p-p-value. Legend: LE-letrozole; CC-clomiphene citrate; N-number
307	of patients; MD-mean difference; SD-standard deviation.
308	S4 Fig. Forest plot for diameter of dominant follicles. Legend: LE-letrozole; CC-
309	clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation.
310	S3 Fig. Forest plot for number of dominant follicles - ovulating patients only. Legend:
311	LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-
312	standard deviation.
313	On the basis of the results of 3 studies including 563 patients, the <b>odds</b> were higher <b>for</b>
314	monofollicular development and lower for multifollicular development in LE patients
315	/monofollicular development: OR=1.99, CI: 0.62-6.34; I <sup>2</sup> =51%, p=0.126 ( <b>S8 Fig</b> ); in the case
316	of multifollicular development: OR=0.50, CI: 0.16-1.61; I <sup>2</sup> =51%, p=0.126 ( <b>S9 Fig</b> )/
317	compared to CC patients, but this difference did not reach the level of statistical significance.
318	S8 Fig. Forest plot for monofollicular development rate. Legend: LE-letrozole; CC-
319	clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value.

- **S9 Fig. Forest plot for multifollicular development rate**. Legend: LE-letrozole; CC-
- 321 clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value.

# **Results of the qualitative analysis**

- 323 Results and main conclusions of the studies only comprised in the systematic review are
- 324 detailed in **Table 2**.

- ----

Author (year)	Endometria I thickness	Endometria I volume	Multilayered endometrial pattern and/or echogenicity	N° of dominant follicles	Diameter of dominan t follicles	Monofollicula r development cycles	Multifollicula r development cycles	Ovulation rate	Pregnancy rate	N° of multiple pregnancie s	N° of miscarriage s	Live birth rate	Prevalenc e of ectopic pregnanc y	N° of fetal anomalie s	endometrial VI, FI VFI or detection rate of endometrial- subendometria l blood flow	RI and PI of subendometria l arteries	SV/DV of subendometria l arteries	RI and PI of uterine arteries	VEGF and/or integrin alpha vß3 concentratio n in uterine fluid
Al- Obaidi et al. [15]	significantly higher in LE group \$	NA	NA	#	#	NA	NA	NA	#	NA	NA	NA	NA	NA	NA	NA	significantly higher in LE group	NA	VEGF has significantly negative correlation with endometrial RI in LE group, no similar correlation was in CC group
Al- Shaikh et al. [47]	significantly higher in CC group	NA	NA	significantl y higher in LE group ¤	no significan t differenc e between LE and CC groups ¤	NA	NA	NA	no significant difference between LE and CC groups ¤	NA	one patient in LE group, 2 in CC group	NA	NA	NA	NA	NA	NA	NA	NA
Amer et al. [48]	significantly higher in CC group	NA	no significant difference between LE and CC group	NA	NA	NA	NA	no significant difference between LE and CC groups, but analyzing the data per cycle significantl y higher in LE group	significantl y higher in LE group	NA	NA	no significant difference between LE and CC groups	NA	none in LE and in CC group	NA	NA	NA	NA	NA
Bansal et al. [55]	no significant difference between LE and CC groups	NA	NA	NA	NA	significantly higher in LE group	NA	no significant difference between LE and CC groups §	significantl y higher in LE group	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Baruah et al. [57]	significantly higher in LE group	NA	NA	no significant difference between LE and CC groups	NA	NA	NA	NA	no significant difference between LE and CC groups ¤	none in LE and in CC group	NA	NA	NA	NA	NA	significantly lower in LE group	NA	NA	NA
Bayar et al. [49]	similar between LE and CC	NA	NA	significantl y lower in LE group	NA	NA	NA	NA	no significant difference	none in LE and CC groups	one patient in LE group	no significant difference	NA	NA	NA	NA	NA	NA	NA

# Table 2. Main conclusions of the studies only included in the systematic review

	groups								between LE and CC groups ¤			between LE and CC groups ¤							
Ghahiri et al. [6]	NA	NA	NA	NA	NA	NA	NA	NA	#	#	#	NA	no significant difference between LE and CC groups	NA	NA	NA	NA	NA	NA
Hussein et al. [42]	significantly higher in LE group \$\$	NA	multilayered endometrial pattern and hypoechogenic endometrium significantly more occurred in LE group (hypoechogeni c endometrium was highly significant associated with pregnancy in both groups)	##	##	NA	NA	NA	##	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Legro et al. [50]	significantly higher in CC group	NA	NA	NA	NA	NA	NA	significantl y higher in LE group	significantl y higher in LE group	no significant difference between two groups	no significant difference between LE and CC groups	significantl y higher in LE group	NA	four patients in LE group and 1 in CC group	NA	NA	NA	NA	NA
Ray et al. [54]	significantly higher in LE group	NA	NA	no significant difference between LE and CC groups ¤	no significan t differenc e between LE and CC groups	majority of induced cycles in LE and CC group	NA	NA	no significant difference between LE and CC groups	NA	one patient in CC group	NA	NA	none in LE and in CC group	NA	NA	NA	NA	NA
Roy et al [51]	significantly higher in LE group	NA	NA	no significant difference between LE and CC groups	NA	NA	NA	similar between LE and CC groups	no significant difference between LE and CC groups ¤	not in LE group, 3 patients in CC group	no significant difference between LE and CC groups	significantl y higher in LE group	NA	NA	NA	NA	NA	NA	NA
Sakar et al. [52]	significantly higher in LE group	NA	NA	similar between LE and CC groups	NA	NA	NA	significantl y higher in LE group ¤	significantl y higher in LE group	not in LE and in CC group	no significant difference between LE and CC groups	significantl y higher in LE group	NA	one patient in LE group and 1 in CC group	NA	NA	NA	NA	NA
Sharief et al. [53]	significantly higher in LE group	NA	NA	significantl y lower in LE group	NA	NA	NA	significantl y higher in LE group	no significant difference between	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

									LE and CC groups										
Wang et al. [1]	#	significantly higher in LE group	multilayered endometrial pattern occurred in LE group significantly more frequently	#	#	NA	NA	#	\$	NA	NA	NA	NA	NA	endometrial VI-FI-and VFI was significantly higher in LE group	#	NA	no significan t differenc e between LE and CC groups	NA
Wang et al. [5]	#	significantly higher in LE group	NA	#	#	NA	NA	#	#	NA	NA	NA	NA	NA	endometrial VI-FI-and VFI were significantly higher in LE group	NA	NA	no significan t differenc e between LE and CC groups	significantly higher in LE group
Dehbash i et al. [56]	#	NA	NA	#	NA	NA	NA	#	#	#	#	no significant difference between LE and CC groups	NA	none in LE group, 1 in CC group	NA	NA	NA	NA	NA
Selim et al. [19]	#	NA	NA	#	NA	NA	NA	#	#	#	NA	NA	NA	NA	rate of endometrial- subendometrial blood flow was significantly lower in LE group	#	NA	NA	NA

N°: number

LE: letrozole

CC: clomiphene citrate

¤: data are given per cycle

§: cumulative ovulation rate

#: data are involved in quantitative analysis in meta-analysis (see in results)

##: data are involved in quantitative analysis in meta-analysis (the studied patient population is the same as in the article by AI-Obaidi et al. 2019 [15], therefore we only included these results once in our meta-analysis; see the results of the AI-Obaidi et al. [15])

\$: the given results could not be used for our quantitative analysis, so we did not include them in our meta-analysis

\$\$: the studied patient population is the same as in the article by Al-Obaidi et al. 2019 [15], but the given results could not be used for our quantitative analysis, so we did not include them in our meta-analysis and we only included these results once in our qualitative analysis in systematic review

#### 344 Quality assessment

- 345 The results of the quality assessment are listed in the Summary of Findings Table (S1 Table
- in the Supplement).

#### 347 **Publication bias**

- 348 No evidence of publication bias was detected (S10-14 Figs in the Supplement).
- 349 The funnel plots do not indicate publication bias and the result of Egger's test was not
- 350 significant, which means publication bias could not be detected. Significant heterogeneity was
- 351 observed for ET, number of dominant follicles and diameter of dominant follicles, RI of
- 352 subendometrial artery, and PI of subendometrial artery. Other outcome measures showed low
- 353 or moderate heterogeneity.

#### 354 **Risk of bias assessment**

355 The results of the risk of bias assessment are shown **S15-70 Figs** in the Supplement.

# 356 **Discussion**

PCOS and infertility caused by PCOS are huge problems worldwide, the treatment of which
has not been solved. Intensive research is underway to find the right drug for ovulation
induction; however, there is no comprehensive summary of the results of the studies so far. In
our study, we summarized the results of the available publications and identified several
positive properties of LE as an ovulation induction drug compared to the currently widely
used CC.

Thicker endometrium is associated with better embryo implantation [20]. ET in our meta-363 analysis was significantly thicker in LE group compared to CC group. When we compared 364 our result with previous meta-analyses by He et al. found that the data of the articles included 365 in the analysis could not be pooled due to significant heterogeneity [58]. However, Gadalla et 366 al. stated that the endometrium was significantly thinner in CC group [11]. Akinoso-Imran et 367 al. found similar results after letrozole treatment [59]. Of the RCTs included in our qualitative 368 analysis (Table 2), six found significantly thicker endometrium in LE group [15, 42, 51-54, 369 370 57], three found significantly thicker endometrium in CC group [47, 48, 50], and two found 371 no significant difference between the two groups [49, 55]. In other studies, the endometrial volume was significantly higher [1, 5] significantly more multilayered endometrial pattern [1, 372 373 42] and hypoechogenic endometrium occurred [42] in LE group. In contrast, one found no significant difference between the two groups in terms of endometrial pattern and 374 echogenicity [48]. 375

Patients taking CC appear to have more but smaller follicles, which may reduce the chance of appropriate maturation, follicle rupture and increase the risk of hyperstimulation and the odds of multiple pregnancies [60]. We found that the number of dominant follicles was higher in patients taking CC, although the definition of dominant follicle differed in the articles (from 12 mm< to 18 mm =/<). The diameters of follicles did not differ significantly; however, the

follicles in LE group were larger. When we compared our results with previous meta-381 382 analyses, we found that He et al. observed significantly fewer mature follicles per cycle in patients taking letrozole [58]. In another study, the standardized mean difference revealed no 383 statistically significant difference between patients treated with LE or CC, but there were also 384 fewer mature follicles in letrozole group [59]. Of the RCTs included in our qualitative 385 analysis (**Table 2**), one found significantly higher numbers of dominant follicles in LE group 386 [47], two found significantly lower numbers in LE group [48, 49], and four found no 387 significant difference between the two groups [51, 52, 54, 57]. As for the diameter of the 388 dominant follicles, two found no significant difference between the two groups [47, 54]. 389 Ovulation is essential for fertilization. We have previously presented that patients in LE group 390 391 had significantly higher odds of ovulation than in CC group. In comparison of our result with 392 previous meta-analyses, He et al. [58], Tsiami et al. [61] and Zhuo et al. [62] reported the same result. Wang et al. pointed out that the ovulation rate was significantly better when 393 394 patients were taking LE instead of CC [63]. In contrast, Roque et al. [64] and Gadalla et al. [11] reported that the odds of ovulation were similar in letrozole group and in CC group. 395 Akinoso-Imran et al. also found that letrozole treatment caused a significantly higher 396 ovulation rate compared to CC [59]. Shifu Hu et al. had similar results [65]. Of the RCTs 397 included in our qualitative analysis (Table 2), three found significantly higher ovulation rates 398 399 in LE group [50, 52, 53], two found no significant difference between the two groups [51, 55]. One found no significant difference in ovulation rate, but when analyzing the data per 400 cycle found, it reported significantly higher in LE group [48]. Another one found the 401 monofollicular development significantly higher [55] in LE group and one found the same 402 majority of cycles included in both groups [54]. 403

It would be good if more women with PCOS increased their chances of getting pregnant. Wefound that the odds of pregnancy were significantly higher in patients treated with letrozole

than in CC group. In comparison of our result with previous meta-analyses, four were found 406 407 to have significantly higher pregnancy rates [59, 62-64] and three were reported to have significantly higher odds of live birth [62-64] after letrozole treatment. Gadalla et al. [11] and 408 Hu et al. [65] described similar differences between the two groups. In contrast, He et al. 409 found no significant difference in the odds of pregnancy between the two groups [58]. Of the 410 RCTs included in our qualitative analysis (Table 2), four found significantly higher 411 pregnancy rates in LE group [48, 50, 52, 55], but the other six found no significant difference 412 between the two groups [47, 49, 51, 53, 54, 57]. Three found significantly higher live birth 413 rates in LE group [50-52], and three found no significant difference between the two groups 414 415 [48, 49, 56].

Multiple pregnancy increases the odds of almost every potential complication of singleton 416 417 pregnancy (e.g. preterm birth, fetal growth restriction, etc.) [66]. In our research, the odds of single pregnancies were higher amongst letrozole patients, and more multiple pregnancies 418 419 occurred amongst CC patients, although this difference did not reach the level of statistical significance. Four previous meta-analyses came to a similar non-significant conclusion [58, 420 59, 63, 65]. In three of the RCTs included in our qualitative analysis (Table 2), no multiple 421 pregnancies occurred in either group [49, 52, 57]. One found no multiple pregnancy in LE 422 group, and three in CC group [51]. One found no significant difference between the two 423 424 groups [50].

The aim should not only be to achieve pregnancy, but also to carry as many pregnancies to term as possible among women with PCOS. In our study, the odds of miscarriage were higher in CC group, but this difference did not reach the level of statistical significance. Our results are consistent with previous meta-analyses in the literature. [58, 59, 63-65]. Of the RCTs included in our qualitative analysis (**Table 2**), three found no significant difference in the number of miscarriages between the two groups [50-52], other studies found no difference or

one or two in groups [47, 49, 54]. In the prevalence of ectopic pregnancy, one found no
significant difference between the two groups [57]. Fetal anomalies were not found in either
group in two RCTs [48, 54], Legro et al. found four in LE group, one in CC group [50], one
found one in LE group, one in CC group [52], one other found no cases in LE group, one in
CC group [56].

The RI of subendometrial arteries was significantly lower in LE group than in CC group. The 436 PI of subendometrial arteries was also lower in patients treated with letrozole, but this result 437 was not statistically significant. With lower RI and PI, intrauterine blood supply is better, and 438 there may be a greater chance of improved intrauterine embryonic development. Wang et al. 439 in their RCT found no difference in PI values between the LE or the CC group after Diane-35 440 and metformin pretreatment (therefore, we did not include these articles in our meta-analysis); 441 442 however, the RI of subendometrial arteries was also significantly lower in LE group [67]. One RCT examined PI and RI of spiral arteries for six months; RI and PI were significantly lower 443 444 in letrozole group [68]. Of the RCTs included in our qualitative analysis (Table 2), one also found significantly lower RI and PI of subendometrial arteries in LE group (they used an 445 increasing drug dose and examined several cycles, so they were not included in our meta-446 analysis) [57]. Two found significantly higher endometrial vascularization index, flow index 447 and vascularization flow index in LE group, and no significant difference in RI and PI of 448 uterine arteries between the two groups [1, 5]. One found that the detection rate of 449 endometrial-subendometrial blood flow was significantly lower in LE group [19]. One found 450 significantly higher systolic velocity/diastolic velocity of subendometrial arteries and a 451 significantly negative correlation in vascular endothelial growth factor concentration with 452 endometrial RI in LE group, although there was no similar correlation in CC group [15]. One 453 found significantly higher vascular endothelial growth factor and integrin alpha vß3 454 concentrations in uterine fluid in LE group [5]. 455

We obtained results similar to the majority of previous meta-analyses, with the difference that 456 457 we also highlighted that a better effect can be achieved with the use of LE compared to CC, even in one cycle. We are the first to use a meta-analysis to confirm the result that the use of 458 LE might be beneficial for subendometrial ciculation compared to CC, which may explain the 459 significant increase in the pregnancy rate among women with PCOS treated with letrozole. 460 The previously mentioned changes in the subendometrial circulation are very early changes 461 after one cycle, which may explain the differences in significance between RI and PI values. 462 With longer-term use, the differences might also become significant for the PI values. 463

#### 464 Strengths and limitations

We used only randomized trials for our meta-analysis. The unique quality of this metaanalysis is that we separated and systematized the results of previous studies on women with PCOS treated with LE or CC according to whether the patients were followed for one or more cycles and whether they received a fixed or increasing drug dose used to induce ovulation. In this way, in contrast to previous meta-analyses, we have reduced the possibility of distortion that could be resulted by a quantitative analysis after combining the above research results. For a quantitative analysis, we found sufficient data only from research studies that used fix

472 doses of the drugs over one cycle.

Only a moderate number of studies could be included because the results of patients examined
over one cycle could not be combined with the total results of patients examined over several
cycles, nor with the results of patients whose medication dose was increased during the
examination, if necessary, in order to provide accurate data. Furthermore, not all eligible
studies used the same drug dose of LE or CC.

478 Another limitation is the presence of moderate and high risk of bias in some of the domains.

#### 479 Implications for practice and research

- 480 The significance of immediate application of research findings in clinical practice cannot be
- 481 underestimated [69]. On the basis of the results of research findings we have analyzed, we can
- 482 claim that LE should be considered for introduction into clinical practice worldwide among
- 483 women with PCOS as a first-line oral ovulation induction drug. On the basis of our very
- 484 encouraging results, we suggest further prospective data collection on subendometrial arterial
- 485 circulation in women with PCOS during their treatment with letrozole for OI.
- 486 In the future, in order to provide more accurate data, it would be important to conduct as
- 487 many research studies with the same number of cycles as possible and to accurately record the
- 488 effects observed with each drug dose, to the extent that the dose of LE and CC is increased
- 489 during the study.

#### Conclusion

- Our results show that letrozole is an effective therapeutic option for the treatment OI in
- patients with PCOS. Comparing LE with CC, which is the gold standard drug for OI, we can
- claim that the administration of LE resulted higher ovulation rates, thicker endometrium,
- lower RI of subendometrial arteries, and higher pregnancy rates. Lower RI in the
- subendometrial arteries can not only increase the chance of embryo implantation but also
- improve embryo development. For the above reasons, we recommend that LE should be

498	considered	as a fi	rst-line	drug for	ovulation	induction
700	constacted	us u 11	ist mit	urug ior	0 v ulution	mauchon

# Acknowledgments

		0		
517	None.			
518				
519				
520				
521				
522				
572				
525				
524				
525				
526				
527				
528				
529				
530				
521				
532				

#### References 533

534 1. Wang L, Wen X, Lv S, Zhao J, Yang T, Yang X. Comparison of endometrial receptivity of clomiphene citrate versus letrozole in women with polycystic ovary syndrome: 535 a randomized controlled study. Gynecol Endocrinol. 2019;35(10):862-5. doi: 536 10.1080/09513590.2019.1612358. PubMed PMID: rayyan-906439176. 537 Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus 538 2. on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam 539 ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 540 2012;97(1):28-38.e25. Epub 20111206. doi: 10.1016/j.fertnstert.2011.09.024. PubMed PMID: 541 22153789. 542 543 3. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293(6543):355-9. doi: 544 10.1136/bmj.293.6543.355. PubMed PMID: 3089520; PubMed Central PMCID: 545 546 PMC1341046. Elsedeek MS-E-A, Elmaghraby HAH, Predictors and characteristics of letrozole 547 4. induced ovulation in comparison with clomiphene induced ovulation in anovulatory PCOS 548 women. Middle East Fertility Society Journal. 2011;16(2):125-30. doi: 549 550 10.1016/j.mefs.2010.11.004. Wang L, Lv S, Li F, Bai E, Yang X, Letrozole Versus Clomiphene Citrate and Natural 551 5. Cycle: Endometrial Receptivity During Implantation Window in Women With Polycystic 552 Ovary Syndrome. 2021(1664-2392 (Print)). 553 Ghahiri A, Mogharehabed N, Mamourian M. Letrozole as the first-line treatment of 554 6. infertile women with poly cystic ovarian syndrome (PCOS) compared with clomiphene 555 citrate: A clinical trial. Adv Biomed Res. 2016;5:6. Epub 20160129. doi: 10.4103/2277-556 9175.175237. PubMed PMID: 26962508; PubMed Central PMCID: PMC4770610. 557 Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence 558 7. and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol 559 Metab. 2004;89(6):2745-9. doi: 10.1210/jc.2003-032046. PubMed PMID: 15181052. 560 Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. 561 8. 2006(0021-972X (Print)). 562 Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 9. 563 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary 564 565 syndrome. 2004(0015-0282 (Print)). Naseri S. The role of Clomiphene citrate in the treatment of infertility. J Mazandaran 10. 566 Univer Med Sci. 2004:14:106-23. 567 Gadalla MA-O, Huang S, Wang R, Norman RJ, Abdullah SA, El Saman AM, et al. 568 11. 569 Effect of clomiphene citrate on endometrial thickness, ovulation, pregnancy and live birth in anovulatory women: systematic review and meta-analysis. Ultrasound in Obstetrics & 570 Gynecogy. 2018(1469-0705):51(1):64-76. doi: 10.1002/uog.18933. 571 Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in 572 12. patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75(2):305-9. 573 doi: 10.1016/s0015-0282(00)01705-2. PubMed PMID: 11172831. 574 Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G. The role 575 13. of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson 576 577 Cancer Center evidence-based approach. Cancer. 2004;101(7):1482-9. doi: 10.1002/cncr.20522. PubMed PMID: 15378476. 578 Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and 579 14. inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J 580 Natl Cancer Inst. 2006;98(18):1285-91. doi: 10.1093/jnci/djj357. PubMed PMID: 16985247. 581

medRxiv preprint doi: https://doi.org/10.1101/2023.09.25.23296113; this version posted September 26, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

15. Al-Obaidi MT, Ali ZH, Saadi Wi AL, Wasiti Ear AL, Al-Aubaidy H. Impact of 582 583 letrozole versus clomiphene citrate on endometrial receptivity in Iraqi women with polycystic ovarian syndrome. Journal of clinical pharmacy and therapeutics. 2019. PubMed PMID: 584 rayyan-906438017. 585 16. Najafi PZ, Noghabi SP, Afzali N, Mohammadzadeh S. Comparing the effect of 586 clomiphene citrate and letrozole on ovulation induction in infertile women with polycystic 587 ovary syndrome. J Pak Med Assoc. 2020;70(2):268-71. doi: 10.5455/jpma.267607. PubMed 588 PMID: rayyan-906438739. 589 17. Gibbs RS, Haney AF. Danforth Obstetrics & Gynecology. China: Lippincott Williams 590 & Wilkins; 2010. 591 Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a 592 18. review of their clinical benefits in the second-line hormonal treatment of advanced breast 593 594 cancer. Ann Oncol. 1999;10(4):377-84. doi: 10.1023/a:1008368300827. PubMed PMID: 595 10370778.

- Selim MF, Borg TF. Letrozole and clomiphene citrate effect on endometrial and 596 19. 597 subendometrial vascularity in treating infertility in women with polycystic ovary syndrome. Journal of Gynecologic Surgery. 2012;28(6):405-10. doi: 10.1089/gyn.2012.0033. PubMed 598
- 599 PMID: rayyan-906438965.
- 600 20. Khan MS, Shaikh A, Ratnani R. Ultrasonography and Doppler Study to Predict Uterine Receptivity in Infertile Patients Undergoing Embryo Transfer. J Obstet Gynaecol 601 India. 2016;66(Suppl 1):377-82. Epub 20150908. doi: 10.1007/s13224-015-0742-5. PubMed 602 603 PMID: 27651633; PubMed Central PMCID: PMC5016392.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. 604 21.
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 605 606 2021;372:n71. Epub 20210329. doi: 10.1136/bmj.n71. PubMed PMID: 33782057; PubMed
- Central PMCID: PMC8005924. 607
- Chandler J, Hopewell S. Cochrane methods--twenty years experience in developing 608 22. systematic review methods. Syst Rev. 2013;2:76. Epub 20130920. doi: 10.1186/2046-4053-2-609
- 76. PubMed PMID: 24050381; PubMed Central PMCID: PMC3849105. 610
- 611 23. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges, and Guiding Treatment. J Clin Endocrinol Metab. 2021;106(3):e1071-e83. doi: 612
- 613 10.1210/clinem/dgaa839. PubMed PMID: 33211867.
- 24. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 614
- 14: Completing 'summary of findings' tables and grading the certainty of the evidence. In 615
- 616 Cochrane Handbook for Systematic Reviews of Interventions. Cochrane: 2022 2022.
- R Core T. R: A Language and Environment for Statistical Computing Vienna, Austria: 617 25.
- R Foundation for Statistical Computing; 2023. Available from: https://www.R-project.org/. 618
- 619 26. Schwarzer G. Meta: General Package for Meta-Analysis 2023. Available from:
- https://github.com/guido-s/meta/ 620
- https://link.springer.com/book/10.1007/978-3-319-21416-0. 621
- Harrer M, Cuijpers P, Ebert D. Doing Meta-Analysis in R. 2019. doi: 622 27.
- 10.5281/zenodo.2551803. 623
- Mantel N, Haenszel W. Statistical Aspects of the Analysis of Data From Retrospective 28. 624
- Studies of Disease. Journal of the National Cancer Institute. 1959;22(4):719-48. doi: 625 626 10.1093/jnci/22.4.719.
- Robins J, Greenland S, N.E. B. A general estimator for the variance of the Mantel-627 29.
- Haenszel odds ratio. American Journal of Epidemiology. 1986:719-23. doi: 628
- 629 10.1093/oxfordjournals.aje.a114447.
- 30. Cooper HM, L.V. H, J.C. V, eds. The Handbook of Research Synthesis and Meta-630
- Analysis. 2nd ed. . New York: Russell Sage Foundation2009. 631

- Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of 632 31. 633 continuity corrections in meta-analysis of sparse data. 2004;23(9):1351-75. doi: 10.1002/sim.1761. 634 Paule RC, Mandel J. Consensus Values and Weighting Factors. Journal of Research of 635 32. the Nacional Bureau of Standards 1982:377-85. doi: 10.6028/jres.087.022. PubMed Central 636 PMCID: PMC6768160. 637 Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. 638 33. Methods to estimate the between-studyvariance and its uncertainty inmeta-analysis. Research 639 640 Synthesis Methods. 2015:55–79. doi: 10.1002/jrsm.1164. Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing Meta-Analysis with R: A 641 34. Hands-On Guide. 1st ed. Boca Raton, FL; London: Chapman & Hall/CRC Press; New York: 642 Chapman and Hall/CRC Press2021. 643 Knapp G, Hartung J. Improved tests for a random effects meta-regression with a 644 35. single covariate. Statistics in Medicine. 2003;22(17):2693-710. doi: 10.1002/sim.1482. 645 IntHout J, J.P.A. I, Borm GF. The Hartung-Knapp-Sidik-Jonkman method forrandom 36. 646 647 effects meta-analysis is straightforwardand considerably outperforms the standardDerSimonian-Laird method. BMC Medical Research Methodology. 2014. 648 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics 649 37. 650 in Medicine. 2002;21(11):1539-58. doi: 10.1002/sim.1186. 38. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by 651 652 a simple, graphical test. BMJ. 1997;315(7109):629-34. doi: 10.1136/bmj.315.7109.629. PubMed PMID: 9310563; PubMed Central PMCID: PMC2127453. 653 Harbord RM, Ross JH, Sterne JAC. Updated Tests for Small-Study Effects in Meta-654 39. Analyses. The Stata Journal: Promoting Communications on Statistics and Stata. 2009:197– 655 656 210. doi: 10.1177/1536867X0900900202. Atay V, Cam C, Muhcu M, Cam M, Karateke A. Comparison of letrozole and 657 40. clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int 658 Med Res. 2006;34(1):73-6. doi: 10.1177/147323000603400109. PubMed PMID: rayyan-659 906438063. 660 Hendawy SF, Samaha HE, Elkholy MF. Letrozole versus Clomiphene Citrate for 41. 661 Induction of Ovulation in Patients with Polycystic Ovarian Syndrome Undergoing 662 663 Intrauterine Insemination. Clin Med Insights Reprod Health. 2011;5:11-6. doi: 10.4137/cmrh.S6598. PubMed PMID: rayyan-906438426. 664 Hussein Z, Al-Obaidi MT, Al-Saadi WI, Selman MO. Comparison of the effect of 42 665 666 clomiphene citrate and letrozole on the endometrial parameters of PCOS women. Journal of pharmaceutical sciences and research. 2017;9(11):2291-5. PubMed PMID: rayyan-667 906438467. 668 669 43. Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: a prospective randomized trial. Journal of human reproductive sciences. 670 2012;5(3):262-5. doi: 10.4103/0974-1208.106338. PubMed PMID: rayyan-906438547. 671 672 44. Khakwani M, Parveen R, Yousaf S, Tareen AU. Efficacy of letrozole versus clomiphene citrate on ovulation induction in patients with polycystic ovarian syndrome. 673 Pakistan journal of medical sciences. 2022;38(5):1155-8. doi: 10.12669/pjms.38.5.5565. 674 675 PubMed PMID: rayyan-906438559. Mobusher I. Comparison of the Efficacy of Letrozole and Clomiphene Citrate for 676 45. Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome. . 905 P J M H S 677 2014; VOL. 8 NO.4 678 Zafar T, Asif F, Naurin R, Majeed T, Mahmood Z. Comparing effectiveness of 679 46.
- letrozole versus clomiphene citrate to evaluate the ovulation induction in patients with 680

polycystic ovarian syndrome. Pakistan journal of medical and health sciences. 681

2021;15(10):2685-8. doi: 10.53350/pjmhs2115102685. PubMed PMID: ravyan-906439302. 682

683 47. Al-Shaikh SFMH, Al-Mukhatar EJ, Al-Zubaidy AA, Al-Rubaie BJU, Al-Khuzaee L. Use of clomiphene or letrozole for treating women with polycystic ovary syndrome related 684

subfertility in Hilla city. Middle East Fertility Society Journal. 2017;22(2):105-10. doi: 685 10.1016/j.mefs.2016.12.003. PubMed PMID: rayyan-906438019. 686

Amer SA, Smith J, Mahran A, Fox P, Fakis A. Double-blind randomized controlled 687 48. trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian 688 syndrome. Hum Reprod. 2017;32(8):1631-8. doi: 10.1093/humrep/dex227. PubMed PMID: 689 28854590; PubMed Central PMCID: PMC5850470. 690

49. Bayar U, Basaran M, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in 691 patients with polycystic ovary syndrome: a prospective randomized trial. Fertility and 692 sterility. 2006;86(5):1447-51. doi: 10.1016/j.fertnstert.2006.04.026. PubMed PMID: rayyan-693 906438107. 694

Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. 695 50. 696 Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-29. doi: 10.1056/NEJMoa1313517. PubMed PMID: rayyan-906438604. 697

Roy KK, Baruah J, Singla S, Sharma JB, Singh N, Jain SK, et al. A prospective 698 51.

699 randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of

ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012;5(1):20-5. doi: 700

10.4103/0974-1208.97789. PubMed PMID: 22870010; PubMed Central PMCID: 701

702 PMC3409915.

Sakar MN, Oglak SC. Letrozole is superior to clomiphene citrate in ovulation 703 52. induction in patients with polycystic ovary syndrome. Pakistan Journal of Medical Sciences. 704 2020:36(7):1460-5. doi: 10.12669/pjms.36.7.3345. PubMed PMID: rayyan-906438951. 705

Sharief M, Nafee NR. Comparison of letrazole and clomiphene citrate in women with 706 53. polycystic ovaries undergoing ovarian stimulation. J Pak Med Assoc. 2015;65(11):1149-52. 707 PubMed PMID: 26564281. 708

Ray PB, Ray A, Chakraborti PS. Comparison of efficacy of letrozole and clomiphene 709 54. citrate in ovulation induction in Indian women with polycystic ovarian syndrome. 2012(1432-710 711 0711 (Electronic)).

712 55. Bansal S, Goyal M, Sharma C, Shekhar S. Letrozole versus clomiphene citrate for

ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized 713 controlled trial. International Journal of Gynaecology and Obstetrics: the official organ of the 714

715 International Federation of Gynaecology and Obstetrics. 2020;152(3):345-50. doi:

10.1002/ijgo.13375. 716

Dehbashi S, Dehbashi, Sa., Kazerooni, T., Robati, M., Alborzi, S., Ebrahim, M., 717 56.

718 Parsanezhad, Shadman, P.A. Comparison of the Effects of Letrozole and Clomiphene Citrate on Ovulation and Pregnancy Rate in Patients with Polycystic Ovary Syndrome. Iranian 719

720 Journal of Medical Sciences. 2009;34 No 1.

Baruah J, Roy KK, Rahman SM, Kumar S, Sharma JB, Karmakar D. Endometrial 721 57. effects of letrozole and clomiphene citrate in women with polycystic ovary syndrome using 722 spiral artery Doppler. Arch Gynecol Obstet. 2009;279(3):311-4. doi: 10.1007/s00404-008-

723 724 0714-4. PubMed PMID: rayyan-906438101.

He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic 725 58. ovary syndrome. Reprod Biomed Online. 2011;23(1):91-6. Epub 20110403. doi: 726

10.1016/j.rbmo.2011.03.024. PubMed PMID: 21550852. 727

59. Akinoso-Imran AQ, Adetunji, H. Systematic review and meta-analysis of letrozole 728 and clomiphene citrate in polycystic ovary syndrome. Middle East Fertility Society Journal. 729

2018. doi: 10.1016/J.MEFS.2018.03.008. 730

60. Mbi Feh MK, Wadhwa, R. Clomiphene. IslandUpdated Jun 27, 2022. 731

732 61. Tsiami AP, Goulis DG, Sotiriadis AI, Kolibianakis EM. Higher ovulation rate with

733 letrozole as compared with clomiphene citrate in infertile women with polycystic ovary

syndrome: a systematic review and meta-analysis. Hormones (Athens). 2021;20(3):449-61. 734

735 Epub 20210525. doi: 10.1007/s42000-021-00289-z. PubMed PMID: 34033068.

62. Liu Z, Geng Y, Huang Y, Hu R, Li F, Song Y, et al. Letrozole Compared With 736

Clomiphene Citrate for Polycystic Ovarian Syndrome: A Systematic Review and Meta-737

analysis. Obstet Gynecol. 2023;141(3):523-34. Epub 20230202. doi: 738

739 10.1097/aog.0000000000005070. PubMed PMID: 36735392.

Wang R, Li W, Bordewijk EM, Legro RS, Zhang H, Wu X, et al. First-line ovulation 740 63.

induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum 741

- 742 Reprod Update. 2019;25(6):717-32. doi: 10.1093/humupd/dmz029. PubMed PMID: 743 31647106.
- Roque M, Tostes AC, Valle M, Sampaio M, Geber S. Letrozole versus clomiphene 744 64.

citrate in polycystic ovary syndrome: systematic review and meta-analysis. Gynecol 745

746 Endocrinol. 2015;31(12):917-21. Epub 20151019. doi: 10.3109/09513590.2015.1096337.

747 PubMed PMID: 26479460.

- Hu S, Yu O, Wang Y, Wang M, Xia W, Zhu C. Letrozole versus clomiphene citrate in 748 65.
- 749 polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch Gynecol

Obstet. 2018;297(5):1081-8. Epub 20180201. doi: 10.1007/s00404-018-4688-6. PubMed 750 751 PMID: 29392438.

- 752 66. Chasen ST. Twin pregnancy: Overview Updated May 22, 2023. Available from: https://www.uptodate.com/contents/twin-pregnancy-overview#.
- 753
- Wang L, Lü SL, Mao WJ, Bai E. Effects of clomiphene citrate and letrozole on uterine 754 67. 755 artery and subendometrial blood flow in patients with polycystic ovarian syndrome. Journal
- of Xi'an Jiaotong University (Medical Sciences). 2017;38(5):734-9. doi: 756
- 757 10.7652/jdyxb201705023. PubMed PMID: rayyan-906439172.

Sharif JH. The Induction of Ovulation in Women with Polycystic Ovarian Syndrome 758 68.

759 Via: Letrozole vs Clomiphene Citrate. Journal of Pharmaceutical Negative Results. 2022;13(1). 760

- Hegyi P, Petersen OH, Holgate S, Erőss B, Garami A, Szakács Z, et al. Academia 761 69.
- 762 Europaea Position Paper on Translational Medicine: The Cycle Model for Translating
- Scientific Results into Community Benefits. J Clin Med. 2020;9(5). Epub 20200519. doi: 763
- 764 10.3390/jcm9051532. PubMed PMID: 32438747; PubMed Central PMCID: PMC7290380.

765

766

# 768 Supporting Information

- 769 S1 Table. Summary of Findings Table. Legend: CI: confidence interval, MD: mean
- 770 difference, OR: odds ratio
- 771 S2 Table. PRISMA 2020 Checklist. Legend: -
- 772 S1 Fig. Forest plot for endometrial thickness (ET) ovulating patients only. Legend: LE-
- 773 letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard
- 774 deviation; CI-confidence interval; p-p-value.
- **S2 Fig. Forest plot for number of dominant follicles all patients.** Legend: LE-letrozole;
- 776 CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation;
- 777 CI-confidence interval; p-p-value.
- **S3 Fig. Forest plot for number of dominant follicles** ovulating patients only. Legend:
  LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SDstandard deviation; CI-confidence interval; p-p-value.
- S4 Fig. Forest plot for diameter of dominant follicles. Legend: LE-letrozole; CCclomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; CIconfidence interval; p-p-value.
- S5 Fig. Forest plot for pregnancy rate ovulating patients only. Legend: LE-letrozole;
  CC-clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-pvalue.
- 787 S6 Fig. Forest plot for multiple pregnancy rate. Legend: LE-letrozole; CC-clomiphene
  788 citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value.
- 789 S7 Fig. Forest plot for miscarriage rate. Legend: LE-letrozole; CC-clomiphene citrate; N790 number of patients; OR-odds ratio; CI-confidence interval; p-p-value.

- 791 S8 Fig: Forest plot for monofollicular development rate. Legend: LE-letrozole; CC-
- round round
- 793 S9 Fig: Forest plot for multifollicular development rate. Legend: LE-letrozole; CC-
- clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value.
- 795 S10 Fig. Funnel plot for endometrial thickness (ET) all patients. Legend: -
- 796 S11 Fig. Funnel plot for ovulation rate. Legend: -
- 797 S12 Fig. Funnel plot for pregnancy rate all patients. Legend: -
- 798 S13 Fig. Funnel plot for resistance index (RI) of subendometrial arteries. Legend: -
- 799 S14 Fig. Funnel plot for pulsatility index (PI) of subendometrial arteries. Legend: -
- 800 S15 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
- endometrial thickness (ET) [1, 4, 5, 16, 19, 41, 43-46, 56] using the revised tool for
  assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -
- 803 : high risk
- 804 S16 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
  805 endometrial thickness (ET) [1, 4, 5, 16, 19, 41, 43-46, 56] broken down to tools, shown in
  806 percentage.
- 807 S17 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing 808 number of dominant follicles [1, 4, 5, 15, 16, 19, 40, 41, 56] using the revised tool for
- assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; i high risk
- S18 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
  number of dominant follicles [1, 4, 5, 15, 16, 19, 40, 41, 56] broken down to tools, shown
  in percentage.

814	S19 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
815	diameter of dominant follicles [1, 5, 15, 16] using the revised tool for assessing risk of
816	bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk
817	S20 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
818	diameter of dominant follicles [1, 5, 15, 16] broken down to tools, shown in percentage.
819	S21 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
820	mono-and multifollicular development [43, 45, 46] rate using the revised tool for
821	assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -
822	: high risk
823	S22 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
824	mono-and multifollicular development [43, 45, 46] rate broken down to tools, shown in
825	percentage.
826	S23 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
827	ovulation rate [1, 4, 5, 19, 42-44, 46, 56] using the revised tool for assessing risk of bias in
828	randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk
829	S24 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
830	ovulation rate [1, 4, 5, 19, 42-44, 46, 56] broken down to tools, shown in percentage.
831	S25 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
832	pregnancy rate [4-6, 15, 16, 19, 40, 42, 43, 45, 56] using the revised tool for assessing risk
833	of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk
834	

835 S26 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
836 pregnancy rate [4-6, 15, 16, 19, 40, 42, 43, 45, 56] broken down to tools, shown in
837 percentage.

838 S27 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
839 single and multiple pregnancy rate [6, 16, 19, 40, 41, 45, 56] using the revised tool for
840 assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; 841 : high risk

S28 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
single and multiple pregnancy rate [6, 16, 19, 40, 41, 45, 56] broken down to tools, shown
in percentage.

845 S29 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
846 rate of miscarriage [6, 16, 43, 56] using the revised tool for assessing risk of bias in

**randomized trials (Rob 2).** Legend: +: low risk; !: some concerns; -: high risk

848 S30 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
849 rate of miscarriage [6, 16, 43, 56] broken down to tools, shown in percentage.

850 S31 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
851 resistance index (RI) of subendometrial arteries [1, 15, 19] using the revised tool for
852 assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -

853 : high risk

854 S32 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
855 resistance index (RI) of subendometrial arteries [1, 15, 19] broken down to tools, shown
856 in percentage.

857 S33 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
858 pulsatility index (PI) of subendometrial arteries [1, 15, 19] using the revised tool for

assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; i high risk

861 S34 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing
862 pulsatility index (PI) of subendometrial arteries [1, 15, 19] broken down to tools, shown
863 in percentage.

864 S35 Fig. Risk of bias assessment of the studies included in the systematic review
865 assessing rate of endometrial thickness (ET) [15, 42, 47-49, 51-55, 57] using the revised
866 tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some
867 concerns; -: high risk

868 S36 Fig. Risk of bias assessment of the studies included in the systematic review

assessing rate of endometrial thickness (ET) [15, 42, 47-49, 51-55, 57] broken down to

870 tools, shown in percentage.

871 S37 Fig. Risk of bias assessment of the studies included in the systematic review
872 assessing endometrial volume (EV) [1, 5] using the revised tool for assessing risk of bias
873 in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

874 S38 Fig. Risk of bias assessment of the studies included in the systematic review
875 assessing endometrial volume (EV) [1, 5] broken down to tools, shown in percentage.

876 S39 Fig. Risk of bias assessment of the studies included in the systematic review
877 assessing endometrial pattern and/or echogenicity [1, 42, 48] using the revised tool for
878 assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; 879 : high risk

880 S40 Fig. Risk of bias assessment of the studies included in the systematic review
881 assessing endometrial pattern and/or echogenicity [1, 42, 48] broken down to tools,
882 shown in percentage.

883 S41 Fig. Risk of bias assessment of the studies included in the systematic review
884 assessing rate of number of dominant follicles [47, 49, 51-54, 57] using the revised tool
885 for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some
886 concerns; -: high risk

887 S42 Fig. Risk of bias assessment of the studies included in the systematic review
888 assessing rate of number of dominant follicles [47, 49, 51-54, 57] broken down to tools,
889 shown in percentage.

890 S43 Fig. Risk of bias assessment of the studies included in the systematic review
891 assessing rate of diameter of dominant follicles [47, 54] using the revised tool for
892 assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; 893 : high risk

894 S44 Fig. Risk of bias assessment of the studies included in the systematic review
895 assessing rate of diameter of dominant follicles [47, 54] broken down to tools, shown in
896 percentage.

897 S45 Fig. Risk of bias assessment of the studies included in the systematic review
898 assessing monofollicular development cycles [54, 55] using the revised tool for assessing
899 risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk
900 S46 Fig. Risk of bias assessment of the studies included in the systematic review
901 assessing monofollicular development cycles [54, 55] broken down to tools, shown in
902 percentage.

903 S47 Fig. Risk of bias assessment of the studies included in the systematic review
904 assessing ovulation rate [48, 50-53, 55] using the revised tool for assessing risk of bias in
905 randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

906 S48 Fig. Risk of bias assessment of the studies included in the systematic review
907 assessing ovulation rate [48, 50-53, 55] broken down to tools, shown in percentage.
908 S49 Fig. Risk of bias assessment of the studies included in the systematic review

assessing pregnancy rate [47-55, 57] using the revised tool for assessing risk of bias in

910 **randomized trials (Rob 2).** Legend: +: low risk; !: some concerns; -: high risk

911 S50 Fig. Risk of bias assessment of the studies included in the systematic review

assessing pregnancy rate [47-55, 57] broken down to tools, shown in percentage.

913 S51 Fig. Risk of bias assessment of the studies included in the systematic review

assessing number of multiple pregnancies [49-52, 57] using the revised tool for assessing

915 risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

916 S52 Fig. Risk of bias assessment of the studies included in the systematic review 917 assessing number of multiple pregnancies [49-52, 57] broken down to tools, shown in 918 percentage.

S53 Fig. Risk of bias assessment of the studies included in the systematic review
assessing number of miscarriages [47, 49-52, 54] using the revised tool for assessing risk
of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

922 S54 Fig. Risk of bias assessment of the studies included in the systematic review 923 assessing number of miscarriages [47, 49-52, 54] broken down to tools, shown in 924 percentage.

925 S55 Fig. Risk of bias assessment of the studies included in the systematic review
926 assessing live birth rate [48-52, 56] using the revised tool for assessing risk of bias in
927 randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

928 S56 Fig. Risk of bias assessment of the studies included in the systematic review 929 assessing live birth rate [48-52, 56] broken down to tools, shown in percentage.

930 S57 Fig. Risk of bias assessment of the studies included in the systematic review

assessing number of ectopic pregnancies [6] using the revised tool for assessing risk of

932 bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

933 S58 Fig. Risk of bias assessment of the studies included in the systematic review
934 assessing number of ectopic pregnancies [6] broken down to tools, shown in percentage.

935 S59 Fig. Risk of bias assessment of the studies included in the systematic review
936 assessing number of fetal anomalies [48, 50, 52, 54, 56] using the revised tool for
937 assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; 938 : high risk

S60 Fig. Risk of bias assessment of the studies included in the systematic review
assessing number of fetal anomalies [48, 50, 52, 54, 56] broken down to tools, shown in
percentage.

942 S61 Fig. Risk of bias assessment of the studies included in the systematic review
943 assessing endometrial vascularization index (VI), flow index (FI), vascularization flow
944 index (VFI) and detection rate of endometrial-subendometrial blood flow [1, 5, 19] using
945 the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low
946 risk; !: some concerns; -: high risk

947 S62 Fig. Risk of bias assessment of the studies included in the systematic review 948 assessing endometrial vascularization index (VI), flow index (FI), vascularization flow 949 index (VFI) detection rate of endometrial-subendometrial blood flow [1, 5, 19] broken 950 down to tools, shown in percentage.

951 S63 Fig. Risk of bias assessment of the studies included in the systematic review
952 assessing systolic velocity (SV)/diastolic velocity (DV) of subendometrial arteries [15]
953 using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +:
954 low risk; !: some concerns; -: high risk

955 S64 Fig. Risk of bias assessment of the studies included in the systematic review 956 assessing systolic velocity (SV)/diastolic velocity (DV) of subendometrial arteries 957 [15]broken down to tools, shown in percentage.

S65 Fig. Risk of bias assessment of the studies included in the systematic review
assessing resistance index (RI) and pulsatility index (PI) of uterine arteries [1, 5] using
the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low
risk; !: some concerns; -: high risk

962 S66 Fig. Risk of bias assessment of the studies included in the systematic review 963 assessing resistance index (RI) and pulsatility index (PI) of uterine arteries [1, 5] broken 964 down to tools, shown in percentage.

965 S67 Fig. Risk of bias assessment of the studies included in the systematic review
966 assessing vascular endothelial growth factor (VEGF) and/or integrin alpha vß3 [5, 15]
967 using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +:
968 low risk; !: some concerns; -: high risk

S68 Fig. Risk of bias assessment of the studies included in the systematic review
assessing vascular endothelial growth factor (VEGF) and/or integrin alpha vß3 [5, 15]
broken down to tools, shown in percentage.

972 S69 Fig. Risk of bias assessment of the studies included in the systematic review
973 assessing resistance index (RI) and pulsatility index (PI) of subendometrial arteries [57]

- 974 using the revised tool for assessing risk of bias in randomized trials (Rob 2) Legend: +:
- 975 low risk; !: some concerns; -: high risk
- 976 S70 Fig. Risk of bias assessment of the studies included in the systematic review
- 977 assessing resistance index (RI) and pulsatility index (PI) of subendometrial arteries [57]
- 978 broken down to tools, shown in percentage. Legend: +: low risk; !: some concerns; -: high
- 979 risk

#### Fig 1. PRISMA (Page et al., 2021) flow diagram



PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources

\*Consider, it leasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). \*\*If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

# Figure

- 4	۰.	ъ	
÷	٩	,	
		~	

Study		LE	group		CC	group	Mana Difference	MD	055 (1	Mainht	Study	Commont	LE	group	CC	group	Offer Parts	08	065 (1	Maight
Study		mean	30		weall	30	mean unreferice	mu	95% (1	weight	study	comment	evenus	rotar	Evenus	rocar	Odds Kabo	OK	90% CI	weight
Dehbashi 2009	50	6.44	1.68	50	7.12	2.01	-	-0.68	[-1.41; 0.05]	9.04%	Al-Obaidi 2019		7	40	12	40		0.49	[0.17; 1.43]	6.89%
Mobusher 2014	50	7.65	1.98	50	7.62	1.95	*	0.03	[-0.74; 0.80]	8.99%	Elsedeek 2011		20	62	16	62		1.37	[0.63; 2.98]	10.67%
Kar 2012	52	7.65	2.10	51	7.61	1.96	+	0.04	[-0.74; 0.82]	8.97%	Ghahiri 2016		29	51	24	52		1.54	[0.71; 3.35]	10.70%
Zafar 2021	180	6.10	1.21	180	5.67	1.17		0.43	[0.18; 0.68]	9.42%	Selim 2012		29	110	20	110		1.61	[0.85; 3.07]	13.41%
Elsedeek 2011	62	8.29	2.23	62	7.25	1.84		1.04	[0.32; 1.76]	9.05%	Hendawy 2011		9	28	5	26		1.99	[0.57; 6.99]	5.24%
Khakwani 2022	39	8.10	1.50	39	6.80	1.90		1.30	[0.54; 2.06]	9.00%	Najafi 2020		45	120	27	120		2.07	[1.17; 3.64]	15.36%
Selim 2012	110	9.90	1.80	110	7.70	1.60		2.20	[1.75; 2.65]	9.30%	Dehbashi 2009		13	50	7	50		2.16	[0.78; 5.98]	7.32%
Wang 2021	57	9.70	2.50	55	6.80	1.90		2.90	[2.08; 3.72]	8.92%	Atay 2006		11	51	5	55	- <del></del>	2.75	[0.88; 8.56]	6.18%
Wang 2019	80	10.70	1,70	80	7.40	1.30	-	3.30	[2.83; 3.77]	9.29%	Mobusher 2014		10	50	4	50	*	2.88	[0.84; 9.88]	5.40%
Najafi 2020	120	11.80	2.70	120	8.30	2.60		3.50	[2.83; 4.17]	9.10%	Kar 2012		11	52	4	51		- 3.15	[0.93; 10.66]	5.51%
Hendawy 2011	28	9.16	1.36	26	4.46	1.71	-	4.70	[3.87; 5.53]	8.92%	Wang 2021		70	90	41	90		4.18	[2.19; 7.99]	13.34%
Random effects model	828			823				1.70	[0.55; 2.86]	100.00%	Random effects model		254	704	165	706	-	1.96	[1.37; 2.81]	100.00%
Prediction interval	Prediction interval				[-2.28; 5.69]		Prediction interval					[0.92; 4.19]								
Heterogeneity; /2 = 97% (9)	Haterogenety: /2 = 97% (95% 95%) x2 = 2.84 .0 < 0.001							Heterogeneity: /2 = 32% [0%: 66%], t2 = 0.09, p = 0.145												
Test for overall effect top	3.28 (	= 0.008)					-4 -2 0 2 4				Test for overall effect: t10 =	4.16 (p = 0.00	2)			0.1	1 0.5 1 2 1	0		
													Pre	Prefers clomichane citrate Prefers latropole						

C)

Prefers clomiphene citrate Prefers letrozole

#### B)

		LE	group	CC	group				
Study	Comment	Events	Total	Events	Total	Odds Ratio	OR	95% CI	Weight
Wang 2019		80	120	80	119		0.97	[0.57; 1.67]	14.50%
Wang 2021		57	90	55	90	- <del>(a  </del>	1.10	[0.60; 2.01]	13.29%
Selim 2012		72	110	64	110	- <del> m </del> -	1.36	[0.79; 2.35]	14.37%
Elsedeek 2011		41	62	35	62		1.51	[0.73; 3.12]	11.18%
Kar 2012		38	52	31	51	-+	1.75	[0.76; 4.02]	9.67%
Atay 2006		42	51	35	55		2.67	[1.08; 6.60]	8.74%
Khakwani 2022		22	39	12	39		2.91	[1.15; 7.37]	8.45%
Dehbashi 2009		30	50	16	50	- <del></del>	3.19	[1.40; 7.24]	9.82%
Zafar 2021		172	180	150	180		- 4.30	[1.91; 9.67]	9.95%
Random effects model		554	754	478	756	-	1.80	[1.21; 2.69]	100.00%
Prediction interval								[0.69; 4.69]	
Heterogenety: /* = 51% [09	6; 77%], t" = 0.	13, p = 0.0	38			02 05 1 2 5			
rest for overall effect. ( a = )	3.36 (p = 0.010	0		-					

Prefers clomiphene citrate Prefers letrozole

LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; OR-odds ratio; CI-confidence interval; p-p-value

# Figure

Fig 3. Forest plots for subendomendometrial circulation: A) resistance index (RI) of subendometrial arteries; B) pulsatility index (PI) of subendometrial arteries

A)





B)



LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; CI-confidence interval; p-p-value

# Figure